Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Market price (% of par)
-
108.52%
-
Total 13F principal
-
$323,081,000
-
Principal change
-
+$8,369,000
-
Total reported market value
-
$353,201,545
-
Number of holders
-
28
-
Value change
-
+$9,517,776
-
Number of buys
-
13
-
Number of sells
-
9
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q3 2022
As of 30 Sep 2022,
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 was held by
28 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$323,081,000
in principal (par value) of the bond.
The largest 10 bondholders included
FRANKLIN RESOURCES INC, BNP PARIBAS ARBITRAGE, SNC, COWEN AND COMPANY, LLC, LAZARD ASSET MANAGEMENT LLC, AVIVA PLC, Antara Capital LP, Kohlberg Kravis Roberts & Co. L.P., UBS OCONNOR LLC, Voya Investment Management LLC, and DeepCurrents Investment Group LLC.
This page lists
28
institutional bondholders reporting positions
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.